Nonmotor outcomes in Parkinson's disease: Is deep brain stimulation better than dopamine replacement therapy?

Therapeutic Advances in Neurological Disorders

Volumn 5, Issue 1, 2012, Pages 23-41

  Borgohain, Rupam ^a   Kandadai, Rukmini Mridula ^a   Jabeen, Afshan ^a   Kannikannan, Meena A ^a  

^a NIZAM'S INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

deep brain stimulation; dopaminergic drugs; globus pallidum interna deep brain stimulation; nonmotor symptoms; Parkinson's disease; pharmacological therapy; subthalamic nucleus deep brain stimulation

Indexed keywords

APOMORPHINE; CABERGOLINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE; LEVODOPA; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE; ROTIGOTINE;

ANXIETY DISORDER; APATHY; BEHAVIOR; BRAIN DEPTH STIMULATION; CARDIAC PATIENT; CARDIOVASCULAR DISEASE; COGNITION; COGNITIVE DEFECT; CONSTIPATION; DEPRESSION; DIGESTIVE SYSTEM FUNCTION DISORDER; DYSPEPSIA; DYSPHAGIA; FLUENCY DISORDER; GASTROINTESTINAL SYMPTOM; GLOBUS PALLIDUS; HALLUCINATION; HUMAN; HYPOMANIA; IMPULSE CONTROL DISORDER; MANIA; MEMORY DISORDER; META ANALYSIS (TOPIC); MORBIDITY; MOTOR DYSFUNCTION; NAUSEA; NOCTURIA; ORTHOSTATIC HYPOTENSION; PAIN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SEXUAL DYSFUNCTION; SINGLE DRUG DOSE; SLEEP DISORDER; STOMACH PARESIS; SUBTHALAMIC NUCLEUS; URINARY FREQUENCY; URINARY URGENCY; VISUAL HALLUCINATION; VOMITING; XEROSTOMIA;

EID: 84858230766     PISSN: 17562856     EISSN: 17562864     Source Type: Journal    
DOI: 10.1177/1756285611423412     Document Type: Review

References (156)

1. Aarsland D. Larsen J.P. Lim N.G. Janvin C. Karlsen K. Tandberg E. et al (1999) Range of neuropsychiatric disturbances in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 67: 492–496.
2. Alberts J.L. Voelcker-Rehage C. Hallahan K. Vitek M. Bamzai R. Vitek J.L. (2008) Bilateral subthalamic stimulation impairs cognitive-motor performance in Parkinson's disease patients. Brain 131: 3348–3360.
3. Allen R.P. Earley C.J. (1996) Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep 19: 205–213.
4. Amara A.W. Watts R.L. Walker H.C. (2011) The effects of deep brain stimulation on sleep in Parkinson's disease. Ther Adv Neurol Disord 4: 15–24.
5. Angyán L. (1994) Somatomotor and cardiorespiratory responses to basal ganglia stimulation in cats. Physiol Behav 56: 167–173.
6. Angyán L. Angyán Z. (1999) Characterization of cardiorespiratory responses to electrical stimulation of the globus pallidus in cat. Physiol Behav 66: 1953–1958.
7. Antonini A. Isaias I.U. Rodolfi G. Landi A. Natuzzi F. Siri C. et al (2011) A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation. J Neurol 258: 579–585.
8. Ardouin C. Voon V. Worbe Y. Abouazar N. Czernecki V. Hosseini H. et al (2006) Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation. Mov Disord 21: 1941–1946.
9. Arnulf I. Bejjani B.P. Garma L. Bonnet A.M. Houeto J.L. Damier P. et al (2000) Improvement of sleep architecture in PD with subthalamic nucleus stimulation. Neurology 55: 1732–1734.
10. Askenasy J.J.M. Yahr M.D. (1985) Reversal of sleep disturbance in Parkinson's disease by antiparkinsonianian therapy: a preliminary study. Neurology 35: 527–532.
11. Barone P. Poewe W. Albrecht S. Debieuvre C. Massey D. Rascol O. et al (2010) Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 9: 573–580.
12. Beiske A.G. Loge J.H. Rønningen A. Svensson E. (2009) Pain in Parkinson's disease: prevalence and characteristics. Pain 141: 173–177.
13. Benarroch E.E. Schmeichel A.M. Parisi J.E. (2000) Involvement of the ventrolateral medulla in parkinsonism with autonomic failure. Neurology 54: 963–968.
14. Beneditti F. Colloca L. Lanotte M. Bergamasco B. Torre E. Lopiano L. (2004) Autonomic and emotional responses to open and hidden stimulations of the human subthalamic region. Brain Res Bull 63: 203–211.
15. Bhattacharya K.F. Nouri S. Olanow C.W. Yahr M.D. Kaufmann H. (2003) Selegiline in the treatment of Parkinson's disease: its impact on orthostatic hypotension. Parkinsonism Relat Disord 9: 221–224.
16. Borgohain R. Mehta N.A. Bajenaru O.A. Quatrale R. Lucini V. Anand R. et al The Study 016 Investigators. (2009) Effect of safinamide on depressive symptoms in patients with mid-late stage Parkinson's disease. Abstracts of the Fourteenth International Congress of Parkinson's Disease and Movement Disorders. Mov Disord 25: S181–S565.
17. Braak H. Ghebremedhin E. Rüb U. Bratzke H. Del Tredici K. (2004) Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 318: 121–134.
18. Brefel-Courbon C. Payoux P. Thalamas C. Ory-Magne F. Slaoui T. Rascol O. et al (2005) Effect of levodopa on pain threshold in Parkinson's disease: a clinical and positron emission tomography study. Mov Disord 20: 1557–1563.
19. Broen M. Duits A. Visser-Vandewalle V. Temel Y. Winogrodzka A. (2011) Impulse control and related disorders in Parkinson's disease patients treated with bilateral subthalamic nucleus stimulation: a review. Parkinsonism Relat Disord 17: 413–417.
20. Bronstein J.M. Tagliati M. Alterman R.L. Lozano A.M. Volkmann J. Stefani A. et al (2011) Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. Arch Neurol 68: 165.
21. Brusa L. Bassi A. Stefani A. Pierantozzi M. Peppe A. Caramia M.D. et al (2003) Pramipexole in comparison to l-dopa: a neuropsychological study. J Neural Transm 110: 373–380.
22. Brusa L. Petta F. Pisani A. Moschella V. Iani C. Stanzione P. et al (2007) Acute vs chronic effects of l-dopa on bladder function in patients with mild Parkinson disease. Neurology 68: 1455–1459.
23. Calne D.B. Brennan J. Spiers A.S.D. Stern G.M. (1960) Hypotension caused by L-dopa. BMJ 1: 474–475.
24. Castelli L. Perozzo P. Genesia M.L. Torre E. Pesare M. Cinquepalmi A. et al (2004) Sexual well being in parkinsonian patients after deep brain stimulation of the subthalamic nucleus. J Neurol Neurosurg Psychiatry 75: 1260–1264.
25. Castelli L. Rizzi L. Zibetti M. Angrisano S. Lanotte M. Lopiano L. (2010) Neuropsychological changes 1-year after subthalamic DBS in PD patients: a prospective controlled study. Parkinsonism Relat Disord 16: 115–118.
26. Castelli L. Zibetti M. Rizzi L. Caglio M. Lanotte M. Lopiano L. (2008) Neuropsychiatric symptoms three years after subthalamic DBS in PD patients: a case-control study. J Neurol 255: 1515–1520.
27. Castner J.E. Chenery H.J. Silburn P.A. Coyne T.J. Sinclair F. Smith E.R. et al (2008) Effects of subthalamic deep brain stimulation on noun / verb generation and selection from competing alternatives in Parkinson's disease. J Neurol Neurosurg Psychiatry 79: 700–705.
28. Chahine L.M. Ahmed A. Sun Z. (2011) Effects of STN DBS for Parkinson's disease on restless legs syndrome and other sleep-related measures. Parkinsonism Relat Disord 17: 208–211.
29. Cicolin A. Lopiano L. Zibetti M. Torre E. Tavella A. Guastamacchia G. et al (2004) Effects of deep brain stimulation of the subthalamic nucleus on sleep architecture in parkinsonian patients. Sleep Med 5: 207–210.
30. Ciucci M.R. Barkmeier-Kraemer J.M. Sherman S.J. (2008) Subthalamic nucleus deep brain stimulation improves deglutition in Parkinson's disease. Mov Disord 23: 676–683.
31. Comella C.L. Morrissey M. Janko K. (2005) Nocturnal activity with nighttime pergolide in Parkinson disease: a controlled study using actigraphy. Neurology 64: 1450–1451.
32. Costa A. Peppe A. Dell'Agnello G. Carlesimo G.A. (2009) Dopamine and cognitive functioning in de novo subjects with Parkinson's disease: effects of pramipexole and pergolide on working memory. Neuropsychologia 47: 1374–1381.
33. Daniele A. Albanese A. Contarino M.F. Zinzi P. Barbier A. Gasparini F. et al (2003) Cognitive and behavioural effects of chronic stimulation of the subthalamic nucleus in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 74: 175–182.
34. Daniels C. Krack P. Volkmann J. Pinsker M.O. Krause M. Tronnier V. et al (2010) Risk factors for executive dysfunction after subthalamic nucleus stimulation in Parkinson's disease. Mov Disord 25: 1583–1589.
35. de Gaspari D. Siri C. Landi A. Cilia R. Bonetti A. Natuzzi F. et al (2006) Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus. J Neurol Neurosurg Psychiatry 77: 450–453.
36. Dellapina E. Gerdelat-Mas A. Ory-Magne F. Pourcel L. Galitzky M. Calvas F. et al (2011) Apomorphine effect on pain threshold in Parkinson's disease: a clinical and positron emission tomography study. Mov Disord 26: 153–157.
37. Deuschl G. Schade-Brittinger C. Krack P. Volkmann J. Schäfer H. Bötzel K. et al (2006) German Parkinson Study Group, Neurostimulation Section. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med 355: 896–908.
38. Drapier D. Drapier S. Sauleau P. Haegelen C. Raoul S. Biseul I. et al (2006) Does subthalamic nucleus stimulation induce apathy in Parkinson's disease?. J Neurol 253: 1081–1093.
39. Erola T. Haapaniemi T. Heikkinen E. Huikuri H. Myllyä V. (2006) Subthalamic nucleus deep brain stimulation does not alter long-term heart rate variability in Parkinson's disease. Clin Auton Res 16: 286–288.
40. Evans A.H. Lees A.J. (2004) Dopamine dysregulation syndrome in Parkinson's disease. Curr Opin Neurol 17: 393–398.
41. Evans A.H. Strafella A.P. Weintraub D. Stacy M. (2009) Impulsive and compulsive behaviors in Parkinson's disease. Mov Disord 24: 1561–1570.
42. Fasano A. Romito L.M. Daniele A. Piano C. Zinno M. Bentivoglio A.R. et al (2010) Motor and cognitive outcome in patients with Parkinson's disease 8 years after subthalamic implants. Brain 133 (9): 2664–2676.
43. Ferreira J.J. Galitzky M. Montastruc J.L. Rascol O. (2000) Sleep attacks and Parkinson's disease treatment. Lancet 355: 1333–1334.
44. Finazzi-Agrò E. Peppe A. D'Amico A. Petta F. Mazzone P. Stanzione P. et al (2003) Effects of subthalamic nucleus stimulation on urodynamic findings in patients with Parkinson's disease. Urology 169: 1388–1391.
45. Follett K.A. Weaver F.M. Stern M. Hur K. Harris C.L. Luo P. et al CSP 468 Study Group. (2010) Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. N Engl J Med 362: 2077–2091.
46. Frankemolle A.M. Wu J. Noecker A.M. Voelcker-Rehage C. Ho J.C. Vitek J.L. et al (2010) Reversing cognitive-motor impairments in Parkinson's disease patients using a computational modelling approach to deep brain stimulation programming. Brain 33: 746–761.
47. Frucht S. Rogers J.D. Greene P.E. Gordon M.F. Fahn S. (1999) Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 52: 1908–1910.
48. Funkiewiez A. Ardouin C. Caputo E. Krack P. Fraix V. Klinger H. et al (2004) Long term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behavior in Parkinson's disease. J Neurol Neurosurg Psychiatry 75: 834–839.
49. Gerdelat-Mas A. Simonetta-Moreau M. Thalamas C. Ory-Magne F. Slaoui T. Rascol O. et al (2007) Levodopa raises objective pain threshold in Parkinson's disease: a RIII reflex study. J Neurol Neurosurg Psychiatry 78: 1140–1142.
50. Gierthmühlen J. Arning P. Binder A. Herzog J. Deuschl G. Wasner G. et al (2010) Influence of deep brain stimulation and levodopa on sensory signs in Parkinson's disease. Mov Disord 25: 1195–1202.
51. Gironell A. Kulisevsky J. Rami L. Fortuny N. García-Sánchez C. Pascual-Sedano B. (2003) Effects of pallidotomy and bilateral subthalamic stimulation on cognitive function in Parkinson disease. A controlled comparative study. J Neurol 250: 917–923.
52. Goetz C.G. Poewe W. Rascol O. Sampaio C. (2005) Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord 20: 523–539.
53. Goldstein D.S. Holmes C.S. Dendi R. Bruce S.R. Li S.T. (2002) Orthostatic hypotension from sympathetic denervation in Parkinson's disease. Neurology 58: 1247–1255.
54. Guo X. Gao G. Wang X. Li L. Li W. Liang Q. et al (2008) Effects of bilateral deep brain stimulation of the subthalamic nucleus on olfactory function in Parkinson's disease patients. Stereotact Funct Neurosurg 86: 237–244.
55. Halpern C.H. Rick J.H. Danish S.F. Grossman M. Baltuch G.H. (2009) Cognition following bilateral deep brain stimulation surgery of the subthalamic nucleus for Parkinson's disease. Int J Geriatr Psychiatry 24: 443–451.
56. Hershey T. Revilla F.J. Wernle A. Gibson P.S. Dowling J.L. Perlmutter J.S. (2004) Stimulation of STN impairs aspects of cognitive control in PD. Neurology 62: 1110–4.
57. Herzog J. Weiss P.H. Assmus A. Wefer B. Seif C. Braun P.M. et al (2006) Subthalamic stimulation modulates cortical control of urinary bladder in Parkinson's disease. Brain 129: 3366–3375.
58. Herzog J. Weiss P.H. Assmus A. Wefer B. Seif C. Braun P.M. et al (2008) Improved sensory gating of urinary bladder afferents in Parkinson's disease following subthalamic stimulation. Brain 131: 132–145.
59. Hjort N. Østergaard K. Dupont E. (2004) Improvement of sleep quality in patients with advanced Parkinson's disease treated with deep brain stimulation of the subthalamic nucleus. Mov Disord 19: 196–199.
60. Holmberg B. Corneliusson O. Elam M. (2005) Bilateral stimulation of nucleus subthalamicus in advanced Parkinson's disease: no effects on, and of, autonomic dysfunction. Mov Disord 20: 976–981.
61. Jahanshahi M. Wilkinson L. Gahir H. Dharminda A. Lagnado D.A. (2010) Medication impairs probabilistic classification learning in Parkinson's disease. Neuropsychologia 48: 1096–1103.
62. Jost W.H. (2003) Autonomic dysfunctions in idiopathic Parkinson's disease. J Neurol 250(Suppl. 1): I28–I30.
63. Kaufmann H. Bhattacharya K.F. Voustianiouk A. Gracies J.M. (2002) Stimulation of the subthalamic nucleus increases heart rate in patients with Parkinson's disease. Neurology 59: 1657–1658.
64. Kim H.J. Paek S.H. Kim J.Y. Lee J.Y. Lim Y.H. Kim M.R. et al (2008) Chronic subthalamic deep brain stimulation improves pain in Parkinson disease. J Neurol 255: 1889–1894.
65. Kim H.J. Park S.Y. Cho Y.J. Hong K.S. Cho J.Y. Seo S.Y. et al (2009) Nonmotor symptoms in de novo Parkinson disease before and after dopaminergic treatment. J Neurol Sci 287: 200–204.
66. Kirsch-Darrow L. Zahodne L.B. Marsiske M. Okun M.S. Foote K.D. Bowers D. (2011) The trajectory of apathy after deep brain stimulation: from pre-surgery to 6 months post-surgery in Parkinson's disease. Parkinsonism Relat Disord 17: 182–188.
67. Klos K.J. Bower J.H. Josephs K.A. Matsumoto J.Y. Ahlskog J.E. (2005) Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy. Parkinsonism Related Disord 11: 381–396.
68. Kujawa K. Leurgans S. Raman R. Blasucci L. Goetz C.G. (2000) Acute orthostatic hypotension when starting dopamine agonists in Parkinson's disease. Arch Neurol 57: 1461–1463.
69. Lawrence A.J. Blackwell A.D. Barker R.A. Spagnolo F. Clark L. Aitken M.R. et al (2007) Predictors of punding in Parkinson's disease: results from a questionnaire survey. Mov Disord 22: 2339–2345.
70. Leentjens A.F. Koester J. Fruh B. Shephard D.T. Barone P. Houben J.J. (2009) The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies. Clin Ther 31: 89–98.
71. Lim S.Y. Lang A.E. (2010) The nonmotor symptoms of Parkinson's disease – an overview. Mov Disord 25(Suppl.1): S123–S130.
72. Lipp A. Tank J. Trottenberg T. Kupsch A. Arnold G. Jordan J. (2005) Sympathetic activation due to deep brain stimulation in the region of the STN. Neurology 65: 774–775.
73. Ludwig J. Remien P. Guballa C. Binder A. Binder S. Schattschneider J. et al (2007) Effects of subthalamic nucleus stimulation and levodopa on the autonomic nervous system in Parkinson's disease. J Neurol Neurosurg Psychiatry 78: 742–745.
74. Lulé D. Heimrath J. Pinkhardt E.H. Ludolph A.C. Uttner I. Kassubek J. (2011) Deep brain stimulation and behavioural changes: is comedication the most important factor?. Neurodegener Dis 2011 21 July [Epub ahead of print].
75. Lyons K.E. Pahwa R. (2006) Effects of bilateral subthalamic nucleus stimulation on sleep, daytime sleepiness, and early morning dystonia in patients with Parkinson disease. J Neurosurg 104: 502–505.
76. Lyytinen J. Sovijärvi A. Kaakkola S. Gordin A. Teräväinen H. (2001) The effect of catechol-O-methyltransferase inhibition with entacapone on cardiovascular autonomic responses in L-Dopa-treated patients with Parkinson's disease. Clin Neuropharmacol 24: 50–57.
77. Maruo T. Saitoh Y. Hosomi K. Kishima H. Shimokawa T. Hirata M. et al (2011) Deep brain stimulation of the subthalamic nucleus improves temperature sensation in patients with Parkinson's disease. Pain 152: 860–865.
78. Micallef J. Rey M. Eusebio A. Audebert C. Rouby F. Jouve E. et al (2009) Antiparkinsonian drug-induced sleepiness: a double-blind placebo-controlled study of L-dopa, bromocriptine and pramipexole in healthy subjects. Br J Clin Pharmacol 67: 333–340.
79. Minguez-Castellanos A. Chamorro C.E. Escamilla-Sevilla F. Ortega-Moreno A. Rebollo A.C. Gomez-Rio M. et al (2007) Do alpha-synuclein aggregates in autonomic plexuses predate Lewy body disorders? A cohort study. Neurology 68: 2012–2018.
80. Morgan J.C. Sethi K.D. (2006) Rotigotine for the treatment of Parkinson's disease. Expert Rev Neurother 6: 1275–1282.
81. Moro E. Lozano A.M. Pollak P. Agid Y. Rehncrona S. Volkmann J. et al (2010) Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease. Mov Disord 25: 578–586.
82. Morrison C.E. Borod J.C. Perrine K. Beric A. Brin M.F. Rezai A. et al (2004) Neuropsychological functioning following bilateral subthalamic nucleus stimulation in Parkinson's disease. Arch Clin Neuropsychol 19: 165–181.
83. Nazem S. Siderowf A.D. Duda J.E. Brown G.K. Ten Have T. Stern M.B. et al (2008) Suicidal and death ideation in Parkinson's disease. Mov Disord 23: 1573–1579.
84. Nazzaro J.M. Pahwa R. Lyons K.E. (2011) The impact of bilateral subthalamic stimulation on on-motor symptoms of Parkinson's disease. Parkinsonism Relat Disord 2011 11 June [Epub ahead of print].
85. Nebe A. Ebersbach G. (2009) Pain intensity on and off levodopa in patients with Parkinson's disease. Mov Disord 24: 1233–1237.
86. Oertel W.H. Wolters E. Sampaio C. Gimenez-Roldan S. Bergamasco B. Dujardin M. et al (2006) Pergolide versus levodopa monotherapy in early Parkinson's disease patients: the PELMOPET study. Mov Disord 21: 343–353.
87. Okun M.S. Fernandez H.H. Wu S.S. Kirsch-Darrow L. Bowers D. Bova F. et al (2009) Cognition and mood in Parkinson's disease in subthalamic nucleus versus globus pallidus interna deep brain stimulation: the COMPARE trial. Ann Neurol 65: 586–595.
88. Olanow C.W. Stern M.B. Sethi K. (2009) The scientific and clinical basis for the treatment of Parkinson's disease. Neurology 72(Suppl. 4): S1–S136.
89. Orimo S. Oka T. Miura H. et al (2002) Sympathetic cardiac denervation in Parkinson's disease and pure autonomic failure but not in multiple system atrophy. J Neurol Neurosurg Psychiatry 73: 776–777.
90. Oyama G. Shimo Y. Natori S. Nakajima M. Ishii H. Arai H. et al (2011) Acute effects of bilateral subthalamic stimulation on decision-making in Parkinson's disease. Parkinsonism Relat Disord 17: 189–193.
91. Pahwa R. Factor S.A. Lyons K.E. Ondo W.G. Gronseth G. Bronte-Stewart H. et al Quality Standards Subcommittee of the American Academy of Neurology. (2006) Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66: 983–995.
92. Pahwa R. Stacy M.A. Factor S.A. Lyons K.E. Stocchi F. Hersh B.P. et al EASE-PD Adjunct Study Investigators. (2007) Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology 68: 1108–1115.
93. Parkinson J. (1817) An Essay on Shaking Palsy, Sherwood, Neely and Jones: London.
94. Parkinson Study Group. (2000) Pramipexole vs levodopa as initial treatment for Parkinson's disease. JAMA 284: 1931–1938.
95. Parsons T.D. Rogers S.A. Braaten A.J. Woods S.P. Tröster A.I. (2006) Cognitive sequelae of subthalamic nucleus deep brain stimulation in Parkinson's disease: a meta-analysis. Lancet Neurol 5: 578–588.
96. Pfeiffer R.F. (2010) Gastrointestinal, urological, and sexual dysfunction in Parkinson's disease. Mov Disord 25(Suppl. 1): S94–S97.
97. Poewe W. (2003) Psychosis in Parkinson's disease. Mov Disord 18(Suppl. 6): S80–S87.
98. Porat O. Cohen O.S. Schwartz R. Hassin-Baer S. (2009) Association of preoperative symptom profile with psychiatric symptoms following subthalamic nucleus stimulation in patients with Parkinson's disease. J Neuropsychiatry Clin Neurosci 21: 398–405.
99. Priori A. Cinnante C. Genitrini S. Pesenti A. Tortora G. Bencini C. et al (2001) Non-motor effects of deep brain stimulation of the subthalamic nucleus in Parkinson's disease: preliminary physiological results. Neurol Sci 22: 85–86.
100. Pursiainen V. Haapaniemi T.H. Korpelainen J.T. Sotaniemi K.A. Myllyla V.V. (2007) Sweating in Parkinsonian patients with wearing-off. Mov Disord 22: 828–832.
101. Rascol O. Brooks D.J. Korczyn A.D. de Deyn P.P. Clarke C.E. Lang A.E. (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levdodopa. N Engl J Med 342: 1484–1491.
102. Rektorová I. Rektor I. Bares M. Dostál V. Ehler E. Fanfrdlová Z. et al (2003) Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study. Eur J Neurol 10: 399–406.
103. Rektorová I. Rektor I. Bares M. Dostál V. Ehler E. Fanfrdlová Z. et al (2005) Cognitive performance in people with Parkinson's disease and mild or moderate depression: effects of dopamine agonists in an add-on to L-dopa therapy. Eur J Neurol 12: 9–15.
104. Rektorová I. Balaz M. Svatova J. Zarubova K. Honig I. Dostal V. et al (2008) Effects of ropinirole on nonmotor symptoms of Parkinson disease: a prospective multicenter study. Clin Neuropharmacol 31: 261–266.
105. Reuter I. Ellis C.M. Ray Chaudhuri K. (1999) Nocturnal subcutaneous apomorphine infusion in Parkinson's disease and restless legs syndrome. Acta Neurol Scand 100: 163–167.
106. Rinne U.K. Bracco F. Chouza C. Dupont E. Gershanik O. Marti Masso J.F. et al PKDS009 Study Group. (1998) Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Drugs 55(Suppl. 1): 23–30.
107. Roane D.M. Yu M. Feinberg T.E. Rogers J.D. (2002) Hypersexuality after pallidal surgery in Parkinson's disease. Neuropsychiatry Neuropsychol Behave Neurol 15: 247–251.
108. Romito L.M. Raja M. Daniele A. Contarino M.F. Bentivoglio A.R. Barbier A. et al (2002) Transient mania with hypersexuality after surgery for high frequency stimulation of the subthalamic nucleus in Parkinson's disease. Mov Disord 17: 1371–1374.
109. Rothlind J.C. Cockshott R.W. Starr P.A. Marks W.J. Jr (2007) Neuropsychological performance following staged bilateral pallidal or subthalamic nucleus deep brain stimulation for Parkinson's disease. J Int Neuropsychol Soc 13: 68–79.
110. Sakakibara R. Uchiyama T. Yamanishi T. Kishi M. (2010) Genitourinary dysfunction in Parkinson's disease. Mov Disord 25: 2–12.
111. Schapira A.H.V. (2000) Sleep attacks (sleep episodes) with pergolide. Lancet 355: 1332–1333.
112. Seif C. Herzog J. van der Horst C. Schrader B. Volkmann J. Deuschl G. et al (2004) Effect of subthalamic deep brain stimulation on the function of the urinary bladder. Ann Neurol 55: 118–120.
113. Shimizu N. Matsumoto S. Mori Y. Yoshioka N. Uemura H. Nakano N. et al (2007) Effects of deep brain stimulation on urodynamic findings in patients with Parkinson's disease. Hinyokika Kiyo 53: 609–612.
114. Slaoui T. Mas-Gerdelat A. Ory-Magne F. Rascol O. Brefel-Courbon C. (2007) Levodopa modifies pain thresholds in Parkinson's disease patients. Rev Neurol 163: 66–71.
115. Smeding H.M. Speelman J.D. Huizenga H.M. Schuurman P.R. Schmand B. (2011) Predictors of cognitive and psychosocial outcome after STN DBS in Parkinson's Disease. J Neurol Neurosurg Psychiatry 82: 754–760.
116. Smeding H.M. Speelman J.D. Koning-Haanstra M. Schuurman P.R. Nijssen P. van Laar T. et al (2006) Neuropsychological effects of bilateral STN stimulation in Parkinson disease: a controlled study. Neurology 66: 1830–1836.
117. Soulas T. Gurruchaga J.M. Palfi S. Cesaro P. Nguyen J.P. Fenelon G. et al (2008) Attempted and completed suicides after subthalamic nucleus stimulation for Parkinson's disease. J Neurol Neurosurg Psychiatry 79: 952–954.
118. Speiser Z. Levy R. Cohen S. (1998) Effects of N-propargyl-1-(R)aminoindan (rasagiline) in models of motor and cognition disorders. J Neural Transm 52(Suppl): 287–300.
119. Stemper B. Beric A. Welsch G. Haendl T. Sterio D. Hilz M.J. (2006) Deep brain stimulation improves orthostatic regulation of patients with Parkinson disease. Neurology 67: 1781–1785.
120. Stiasny-Kolster K. Kohnen R. Schollmayer E. Moller J.C. Oertel W.H. Rotigotine Sp 666 Study Group. (2004) Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: a double-blind, placebo-controlled pilot study. Mov Disord 19: 1432–1438.
121. Stowe R. Ives N. Clarke C.E. Handley K. Furmston A. Deane K. et al (2011) Meta-analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson's disease. Mov Disord 26: 587–598.
122. Stowe R.L. Ives N.J. Clarke C. van Hilten J. Ferreira J. Hawker R.J. et al (2008) Dopamine agonist therapy in early Parkinson's disease. Cochrane Database Syst Rev 2008 (2): CD006564.
123. Strutt A.M. Simpson R. Jankovic J. York M.K. (2011) Changes in cognitive-emotional and physiological symptoms of depression following STN-DBS for the treatment of Parkinson's disease. Eur J Neurol 11 Jun doi: 10.1111/j.1468-1331.2011.03447.x10.1111/j.1468-1331.2011.03447.x [Epub ahead of print].
124. Swinn L. Schrag A. Viswanathan R. (2003) Sweating dysfunction in Parkinson's disease. Mov Disord 18: 1459–1463.
125. Takahata K. Minami A. Kusumoto H. Shimazu S. Yoneda F. (2005) Effects of selegiline alone or with donepezil on memory impairment in rats. Eur J Pharmacol 518: 140–144.
126. Takeshita S. Kurisu K. Trop L. Arita K. Akimitsu T. Verhoeff N.P. (2005) Effect of subthalamic stimulation on mood state in Parkinson's disease: evaluation of previous facts and problems. Neurosurg Rev 28: 179–186.
127. Tateno F. Sakakibara R. Yokoi Y. Kishi M. Ogawa E. Uchiyama T. et al (2011) Levodopa ameliorated anorectal constipation in de novo Parkinson's disease: the QL-GAT study. Parkinsonism Relat Disord 2011 24 June [Epub ahead of print].
128. Temel Y. Kessels A. Tan S. Topdag A. Boon P. Visser-Vandewalle V. (2006) Behavioural changes after bilateral subthalamic stimulation in advanced Parkinson disease: a systematic review. Parkinsonism Relat Disord 12: 265–272.
129. Thobois S. Ardouin C. Lhommée E. Klinger H. Lagrange C. Xie J. et al (2010) Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation. Brain 133: 1111–1127.
130. Thornton J.M. Aziz T. Schlugman D. Paterson D.J. (2002) Electrical stimulation of the midbrain increases heart rate and arterial blood pressure in awake humans. J Physiol 539: 615–621.
131. Trachani E. Constantoyannis C. Sirrou V. Kefalopoulou Z. Markaki E. Chroni E. (2010) Effects of subthalamic nucleus deep brain stimulation on sweating function in Parkinson's disease. Clin Neurol Neurosurg 112: 213–217.
132. Trenkwalder C. Kies B. Rudzinska M. Fine J. Nikl J. Honczarenko K. et al Recover Study Group. (2011) Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 26: 90–99.
133. Vignatelli L. Billiard M. Clarenbach P. Garcia-Borreguero D. Kaynak D. Liesiene V. et al EFNS Task Force. (2006) EFNS guidelines on management of restless legs syndrome and periodic limb movement disorder in sleep. Eur J Neurol 13: 1049–1065.
134. Visser M. Marinus J. Stiggelbout A.M. van Hilten J.J. (2004) Assessment of autonomic dysfunction in Parkinson's disease: the SCOPAAUT. Mov Disord 19: 1306–1312.
135. Volkmann J. Albanese A. Kulisevsky J. Tornqvist A.L. Houeto J.L. Pidoux B. et al (2009) Long-term effects of pallidal or subthalamic deep brain stimulation on quality of life in Parkinson's disease. Mov Disord 24: 1154–1161.
136. Voon V. Kubu C. Krack P. Houeto J.L. Tröster A.I. (2006) Deep brain stimulation: neuropsychological and neuropsychiatric issues. Mov Disord 21(Suppl. 14): S305–S327.
137. Voon V. Krack P. Lang A.E. Lozano A.M. Dujardin K. Schüpbach M. et al (2008) A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease. Brain 31: 2720–2728.
138. Walters A.S. Ondo W.G. Dreykluft T. Grunstein R. Lee D. Sethi K. (2004) Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo controlled study. Mov Disord 19: 1414–1423.
139. Wang X. Chang C. Geng N. Li N. Wang J. Ma J. et al (2009) Long-term effects of bilateral deep brain stimulation of the subthalamic nucleus on depression in patients with Parkinson's disease. Parkinsonism Relat Disord 15: 587–591.
140. Weaver F.M. Follett K. Stern M. Hur K. Harris C. Marks W.J. Jr et al CSP 468 Study Group. (2009) Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA 301: 63–73.
141. Weintraub D. Siderowf A.D. Potenza M.N. Goveas J. Morales K.H. Duda J.E. et al (2006) Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol 63 (7): 969–73.
142. Weintraub D. Koester J. Potenza M.N. Siderowf A.D. Stacy M. Voon V. et al (2010) Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 67: 589–595.
143. Williams A. Gill S. Varma T. Jenkinson C. Quinn N. Mitchell R. et al PD SURG Collaborative Group. (2010) Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trial. Lancet Neurol 9: 581–591.
144. Williams A.E. Arzola G.M. Strutt A.M. Simpson R. Jankovic J. York M.K. (2011) Cognitive outcome and reliable change indices two years following bilateral subthalamic nucleus deep brain stimulation. Parkinsonism Relat Disord 17: 321–327.
145. Winge K. Fowler C.J. (2006) Bladder dysfunction in Parkinsonism: mechanisms, prevalence, symptoms, and management. Mov Disord 21: 737–745.
146. Winge K. Nielsen K.K. Stimpel H. Lokkegaard A. Jensen S.R. Werdelin L. (2007) Lower urinary tract symptoms and bladder control in advanced Parkinson's disease: effects of deep brain stimulation in the subthalamic nucleus. Mov Disord 22: 220–225.
147. Winge K. Werdelin L.M. Nielsen K.K. Stimpel H. (2004) Effects of dopaminergic treatment on bladder function in Parkinson's disease. Neurourol Urodyn 23: 689–696.
148. Winkelman J.W. Sethi K.D. Kushida C.A. Becker P.M. Koester J. Cappola J.J. et al (2006) Efficacy and safety of pramipexole in restless legs syndrome. Neurology 67: 1034–1039.
149. Witjas T. Kaphan E. Régis J. Jouve E. Chérif A.A. Péragut J.C. et al (2007) Effects of chronic subthalamic stimulation on nonmotor fluctuations in Parkinson's disease. Mov Disord 22: 1729–1734.
150. Witt K. Daniels C. Reiff J. Krack P. Volkmann J. Pinsker M.O. et al (2008) Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson's disease: a randomised, multicentre study. Lancet Neurol 7: 605–614.
151. York M.K. Dulay M. Macias A. Levin H.S. Grossman R. Simpson R. et al (2008) Cognitive declines following bilateral subthalamic nucleus deep brain stimulation for the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 79: 789–795.
152. Youdim M.B. Bakhle Y.S. (2006) Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness. Br J Pharmacol 147(Suppl. 1): S287–S296.
153. Zangaglia R. Pacchetti C. Pasotti C. Mancini F. Servello D. Sinforiani E. et al (2009) Deep brain stimulation and cognitive functions in Parkinson's disease: a three-year controlled study. Mov Disord 24: 1621–1628.
154. Zgaljardic D.J. Borod J.C. Foldi N.S. Mattis P. (2003) A review of the cognitive and behavioral sequelae of Parkinson's disease: relationship to frontostriatal circuitry. Cogn Behav Neurol 16: 193–210.
155. Zibetti M. Torre E. Cinquepalmi A. Rosso M. Ducati A. Bergamasco B. et al (2007) Motor and nonmotor symptom follow-up in parkinsonian patients after deep brain stimulation of the subthalamic nucleus. Eur Neurol 58: 218–223.
156. Ziemssen T. Reichmann H. (2007) Non-motor dysfunction in Parkinson's disease. Parkinsonism Relat Disord 13: 323–332.